Searched for
YESAFILI
USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...21 May, 2024, 12.12 PM IST- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...04 Mar, 2024, 11.47 AM IST
Load More